Interview 31 Oct 2022
AI and biobanks could open the way to longevity treatments
The development of longevity treatments is hampered by a lack of biomarkers and validated drug targets. BioAge’s co-founder and CEO, Kristen Fortney, explains how the firm is enlisting machine learning (ML), artificial intelligence (AI) and biobanks to fill in the gaps. The quest for human longevity treatments is attracting big cash in the biotech industry. […]